Tuberculosis

Antimycobacterial agent NOT absorbed orally:
1. isoniazid (INH)
2. streptomycin
3. rifampin (Rimactane)
4. ethambutol (Myambutol)
Liver toxicity (hepatoxic)
1. isoniazid (INH)
2. rifampin (Rimactane)
3. both
4. neither
Auditory deficits:
1. steptomycin
2. ethambutol (Myambutol)
3. both
4. neither
Aminoglycoside agent useful in management of tuberculosis
1. ethambutol (Myambutol)
2. streptomycin
3. isoniazid (INH)
4. cycloserine
Hepatotoxic given at normal doses for extended periods for treatment of tuberculosis:
1. streptomycin
2. para-aminosalicylic acid (PAS)
3. isoniazid (INH)
4. B & C
Decreases likelihood of resistance to other antituberculosis drugs:
1. rifampin (Rimactane)
2. ethambutol (Myambutol)
3. streptomycin
4. isoniazid (INH)
Most significant antituberculosis drug:
1. rifampin (Rimactane)
2. saquinavir (Invirase)
3. isoniazid (INH)
4. streptomycin
Minimum treatment duration for active TB
1. one to three months
2. six to nine months
3. for life
4. five years
Isoniazid (INH)
1. tuberculostatic agent
2. neurotoxicity
3. well-absorbed from the GI tract
4. all of the above
Primary drugs for treating tuberculosis:
1. PAS
2. ethambutol (Myambutol)
3. rifampin (Rimactane)
4. all of the above
"Fast and slow acetylators" influence this (these) drug's metabolism:
1. penicillin
2. sulfonamides
3. isoniazid (INH)
4. B & C
NOT a side effect of isoniazid (INH):
1. hepatotoxicity
2. allergic reactions
3. peripheral neuritis
4. nephrotoxicity
Following oral administration, blood brain barrier prevents effective treatment of CNS tuberculosis:
1. rifampin (Rimactane) to
2. ethambutol (Myambutol)
3. isoniazid (INH)
4. streptomycin
Ethambutol (Myambutol) (in combination with isoniazid (INH)) exhibits adverse effects especially directed to this organ:
1. hepatic toxicity
2. nephrotoxicity
3. ocular toxicity
4. splenic toxicity
Mechanism of action: isoniazid (INH)
1. competitive inhibitor with PABA
2. mycolic acid synthesis inhibitor
3. inhibits RNA polymerase (binds to the polymerase.
4. blocks protein synthesis like chloramphenicol (Chloromycetin)
Mechanism of action: streptomycin
1. blocks reverse transcriptase
2. blocks protein synthesis
3. blocks RNA polymerase
4. blocks the topoisomerase enzyme
Mechanism of Action:PAS (para-aminosalicyclic acid)
1. PABA competitor
2. protein synthesis inhibitor
3. DNA polymerase inhibitor
4. inhibitor of cell wall synthesis
Mechanim of action: rifampin (Rimactane)
1. PABA competitor
2. mcolic acid synthesis
3. inhibits RNA synthesis by binding to DNA dependent RNA polymerase
4. none of the above
NOT an appropriate use for rifampin (Rimactane):
1. treatment of leprosy (with a sulfone)
2. treatment of meningococcal carriers
3. prophylaxis for exposure to H. influenzae
4. Pseudomonal bacteriostasis
Leprosy drug therapy:
1. dapsone
2. rifampin (Rimactane)
3. pyrimethamine (Daraprim)
4. all of the above